Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology
JCO Precision Oncology · 2024
DOI: 10.1200/po.24.00363 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Alexander D Sherry und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The primary results of phase III oncology trials may be challenging to interpret, given that results are generally based on P value thresholds. The probability of whether a treatment is beneficial, although more intuitive, is not usually provided. Here, we developed and released a user-friendly tool that calculates the probability of treatment benefit using trial summary statistics. METHODS We curated 415 phase III randomized trials enrolling 338,600 patients published between 2004 and 2020. A phase III prior probability distribution for the treatment effect was developed on the basis of a three-component zero-mean mixture distribution of the observed z-scores. Using this prior, we computed the probability of clinically meaningful benefit (hazard ratio [HR]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
- Department of Radiation Oncology, Stanford University, Stanford, CA.
- Insitro, South San Francisco, CA.
ORCID-Profile: Alexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, Timothy A Lin, Ramez Kouzy, Zachary R McCaw, Ethan B Ludmir, Erik van Zwet
Förderung
- NCI NIH HHS
Zitieren
APA
Sherry, A. D., Msaouel, P., Kupferman, G. S., Lin, T. A., Abi Jaoude, J., Kouzy, R., McCaw, Z. R., Ludmir, E. B., & van Zwet, E. (2024). Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology. JCO Precision Oncology. https://doi.org/10.1200/po.24.00363
Vancouver
Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, et al. Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology. JCO Precision Oncology. 2024. doi:10.1200/po.24.00363
BibTeX
@article{Sherry2024,
author = {Sherry, Alexander D and Msaouel, Pavlos and Kupferman, Gabrielle S and Lin, Timothy A and Abi Jaoude, Joseph and Kouzy, Ramez and McCaw, Zachary R and Ludmir, Ethan B and van Zwet, Erik},
title = {Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.24.00363}
}
EUVIMED